Emapalumab and eltrombopag rescue for prolonged immune effector cell-associated hemophagocytic syndrome after CAR T-cell therapy in multiple myeloma
Authors
- Shafinaz Hussein (ORCID: https://orcid.org/0000-0002-7063-1858)
- Christian Salib (ORCID: https://orcid.org/0000-0001-5466-6949)
- Shambavi Richard (ORCID: https://orcid.org/0000-0003-0274-4292)
- S Jagannath
- Tarek H. Mouhieddine (ORCID: https://orcid.org/0000-0002-1190-5978)
- Adolfo Aleman (ORCID: https://orcid.org/0000-0002-8884-2100)
- Alessandro Laganà (ORCID: https://orcid.org/0000-0003-1134-0564)
- Amy Duffield (ORCID: https://orcid.org/0009-0006-6683-8780)
- Samir Parekh
- Junia Vieira Dos Santos
- Harshita Sehgal
Institutions
- Dana-Farber Cancer Institute (US)
- Tisch Hospital (US)
- Icahn School of Medicine at Mount Sinai (US)
Funders
- AstraZeneca
- Sanofi
- Celgene
- Karyopharm Therapeutics
- Regeneron Pharmaceuticals
- Genentech
- Legend Biotech
- National Cancer Institute